Bayer flags major Phase III results for stroke prevention drug asundexian
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
Research by NITI Aayog and All India Institute of Medical Sciences has shown that at least 30% of trauma deaths are linked to delays in emergency response
The new unit is expected to serve thousands of patients annually, helping address a critical gap in dialysis access
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform
Subscribe To Our Newsletter & Stay Updated